详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Programmed Cell Death Protein Ligand 2 Is a Potential Biomarker That Predicts the Efficacy of Immunotherapy.

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Institute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, China [2]Chongqing Key Laboratory of Tumor Immunotherapy, Chongqing 400037, China [3]Center of Growth, Metabolism and Aging, Key Laboratory of Bio-Resources and Eco-Environment, College of Life Sciences, Sichuan University, Chengdu 610064, China [4]Research Institute, GloriousMed Clinical Laboratory (Shanghai) Co., Ltd., Shanghai 201318, China

出处：

DOI：

ISSN：

摘要：

Immune checkpoint inhibitor (ICI) responses vary, and biomarkers for predicting responders are urgently needed. Growing evidence points to the association between programmed cell death protein ligand 2 (PDL2) and ICI benefits, while clinical evidences were lacking. Thus, we consolidated five public ICI-treated cohorts to investigate the association between PDL2 expression and ICI treatment prognosis. Immune cell signatures and IFN-γ signatures are investigated in The Cancer Genome Atlas (TCGA) dataset and later in ICI-treated cohorts to explore the association between PDL2 and antitumor immunity in the tumor microenvironment (TME). We found that immune cell signatures and IFN-γ signatures were enriched in the PDL2-high group in TCGA pooled cohorts and most cancers. Consistently, in ICI-treated cohorts, patients with high PDL2 expression experienced longer overall survival time (OS) and were more likely responsive to ICIs than patients with low PDL2 expression. Immune cell scores of the high PDL2 expression patients were significantly higher (P < 0.05) than those of the low PDL2 expression patients in ICI-treated cohorts. In conclusion, our findings suggest that PDL2 is a potential predictive biomarker for ICIs.Copyright © 2021 Aoyun Wang et al.

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 4 区医学

小类 | 4 区生物工程与应用微生物 4 区遗传学 4 区医学：研究与实验 4 区病理学

最新[2023]版：

无

第一作者：

第一作者机构： [1]Institute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, China [2]Chongqing Key Laboratory of Tumor Immunotherapy, Chongqing 400037, China

共同第一作者：

通讯作者：

通讯机构： [1]Institute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, China [2]Chongqing Key Laboratory of Tumor Immunotherapy, Chongqing 400037, China

推荐引用方式(GB/T 7714)：

APA：

MLA：